Viking Therapeutics at Bernstein Forum: Strategic Moves in Obesity Market

Viking Therapeutics (VKTX) outlined significant progress in its obesity pipeline at the Bernstein Healthcare Forum, particularly for its dual GLP-1/GIP receptor agonist, VK2735. The subcutaneous formulation is now in Phase 3 trials (VANQUISH 1 and 2) after demonstrating approximately 15% weight loss in Phase 2, while the oral formulation successfully completed its Phase 2 study with up to 12% weight loss, and an End-of-Phase 2 FDA meeting is scheduled for Q4 to plan its Phase 3 development. With over $800 million in cash, Viking is well-capitalized to fund these trials and aims to compete in the expanding obesity market by exploring combination therapies and a direct-to-patient commercial model.

Analysis

Viking Therapeutics (VKTX) presented a detailed roadmap for its obesity pipeline, underscoring significant progress and a strong financial position. The company's lead asset, VK2735, a dual GLP-1/GIP receptor agonist, is advancing on two fronts. The subcutaneous formulation, which demonstrated approximately 15% weight loss in 13 weeks during Phase 2, is now in two large-scale Phase 3 trials (VANQUISH 1 and 2), with a slower four-week titration schedule designed to enhance tolerability. Concurrently, the oral formulation of VK2735 has completed a successful Phase 2 study, achieving up to 12% weight loss at 13 weeks and demonstrating proof-of-concept for a high-to-low dose maintenance strategy. A critical catalyst is the upcoming end-of-Phase 2 FDA meeting in Q4, which will clarify the path to Phase 3 for the oral version. Financially, the company is well-capitalized with over $800 million in cash, providing a sufficient runway to complete the ongoing Phase 3 trials without near-term financing risk. Strategically, Viking is positioning to compete on efficacy, which it views as the primary market driver, while also exploring a capital-efficient direct-to-patient commercial model and next-generation combination therapies with its amylin agonist program.

Key Decisions for Investors

• Investors should monitor for the outcome of the Q4 end-of-Phase 2 FDA meeting for oral VK2735, as this will be a key catalyst defining the regulatory pathway, trial design, and timeline for its Phase 3 program.
• Given the promising efficacy data from both formulations and a robust cash position of over $800 million, evaluate Viking's competitive positioning against incumbent obesity treatments, focusing on the comparative weight loss and tolerability profiles that will emerge from the VANQUISH Phase 3 trials.
• Consider the long-term strategic optionality, including the potential for a capital-light direct-to-patient commercial launch and the development of a next-generation combination therapy involving the company's amylin agonist, which could further enhance efficacy.
• It is prudent to track enrollment progress and patient retention data from the ongoing Phase 3 trials, as successful execution and management of placebo-group dropout are critical risks in the increasingly competitive obesity market.